awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51B
Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51B
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
P2860
Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34438769-07642DAD-FBCE-406F-BB1E-43084412D51B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
367777fd85f005721333335a6bdfc9f3c9398b17
P2860
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.